Arlene Weintraub

Arlene Weintraub
Arlene Weintraub
Contributing Writer

Arlene Weintraub has over 15 years of experience writing about health care, pharmaceuticals and biotechnology. Her freelance pieces have been published in the New York Times, US News & World Report, Technology Review, Scientific American, USA Today, Entrepreneur.com, FierceMarkets and other media outlets. She was previously a senior health writer for BusinessWeek, covering both the science and business of health. She also worked as an editor for Xconomy.com, covering the biotech industry, as well as technology, life sciences and clean technology companies. She has won awards from the New York Press Club, the Association of Health Care Journalists, the Foundation for Biomedical Research, and the American Society of Business Publication Editors. Her book about the antiaging industry, Selling the Fountain of Youth, was published by Basic Books in 2010.

Stories by Arlene Weintraub

Targeting immune cells could treat diabetes and high blood pressure

Specialized immune cells called eosinophils are prevalent in the fatty tissue that surrounds blood vessels and helps them operate normally. Now a group of British researchers has discovered that these cells are greatly diminished in obesity—and that their absence contributes to Type 2 diabetes and hypertension.
Lungs

BI teams with Vanderbilt U to pursue novel cancer attack against KRAS

Mutations in a gene called KRAS are found in up to 25% of lung cancers, 45% of colon tumors and 90% of pancreatic cancers. Yet after three decades of research, no effective treatments targeting KRAS mutations have been developed. Germany’s Boehringer Ingelheim hopes to turn around that streak of bad luck via a partnership it has formed with Vanderbilt University.
Cancer

Fred Hutch scientists use ‘barcode’ system to find cancer-killing T cells

One big challenge of using T cells to treat cancer is that each infusion contains thousands of different varieties of the cells, some of which are much more effective at killing cancer than others are. So scientists at the Fred Hutchinson Cancer Research Center in Seattle have come up with a new way to find the cells that are most likely to lead the attack against tumors.
cancer

‘Spiderweb’ of lung cancer proteins snares new drug targets

Scientists at Emory University’s Winship Cancer Institute are on a mission to unlock the mysteries of lung cancer cells that have long been thought to be unresponsive to any drug therapy. So they’ve developed what they call a “spiderweb of interactions” between proteins in those cancer cells, and they’re using the data to figure out how to target cancer mutations in the lung.